AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

The advent of amyloid-β (Aβ) and tau PET imaging has revolutionized Alzheimer disease (AD) research, enabling in vivo ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

The spending watchdog deemed the drug's benefits 'too small' to justify the cost of making it available on the NHS ...

Home Instead chief executive Martin Jones said: “Dementia has now eclipsed cancer as our greatest health fear for the future.

Early evidence links some Alzheimer’s Disease medications to small cognitive gains in children with autism and low IQ, ...

Donanemab—one of the two breakthrough therapies hailed globally for showing promising results in treating Alzheimer's disease—has been approved by India's apex drug regulator, and its maker Eli Lilly ...